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Abstract
Background: N-terminal acetylation is a common protein modification in human cells and is catalysed by N-
terminal acetyltransferases (NATs), mostly cotranslationally. The NAA10-NAA15 (NatA) protein complex is the major
NAT, responsible for acetylating ~ 40% of human proteins. Recently, NAA10 germline variants were found in patients
with the X-linked lethal Ogden syndrome, and in other familial or de novo cases with variable degrees of
developmental delay, intellectual disability (ID) and cardiac anomalies.
Methods: Here we report a novel NAA10 (NM_003491.3) c.248G > A, p.(R83H) missense variant in NAA10 which was
detected by whole exome sequencing in two unrelated boys with intellectual disability, developmental delay,
ADHD like behaviour, very limited speech and cardiac abnormalities. We employ in vitro acetylation assays to
functionally test the impact of this variant on NAA10 enzyme activity.
Results: Functional characterization of NAA10-R83H by in vitro acetylation assays revealed a reduced enzymatic
activity of monomeric NAA10-R83H. This variant is modelled to have an altered charge density in the acetyl-
coenzyme A (Ac-CoA) binding region of NAA10.
Conclusions: We show that NAA10-R83H has a reduced monomeric catalytic activity, likely due to impaired
enzyme-Ac-CoA binding. Our data support a model where reduced NAA10 and/or NatA activity cause the
phenotypes observed in the two patients.
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Background
N-terminal acetylation (Nt-acetylation) is an exceedingly
prevalent protein modification, affecting an estimated
80% of human proteins [1]. An acetyl group donated by
acetyl coenzyme A (Ac-CoA) is attached to the N-terminal
amine group of a substrate protein through the catalytic
action of N-terminal acetyltransferases (NATs), which are
members of the GCN5-related N-acetyltransfererase
(GNAT) superfamily [2]. Nt-acetylation may affect
substrates in several ways, although for most substrates the
importance of the Nt-acetyl group remains enigmatic.
Nt-acetylation is reported to affect the half-life of substrates,
destabilizing some substrates [3–5] and stabilizing others [6,
7]. Nt-acetylation also regulates folding [8–11], protein com-
plex formation [12–17], subcellular localization and mem-
brane interaction [16–19]. While several post-translational
NATs have recently been described [20–25], most substrates
appear to be Nt-acetylated at the ribosome by one of at least
five ribosome-associated NATs – NatA, NatB, NatC, NatD,
or NatE. Chief among these in terms of substrate diversity is
NatA [1]. The human NatA complex is composed of the
catalytic subunit NAA10 and the auxiliary subunits NAA15,
NAA50 and HYPK [11, 26–29]. The ribosome-associated
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NatA complex Nt-acetylates an estimated 40% of the hu-
man proteome [30], preferring small, polar amino acids
which are exposed after initiator methionine excision [26].
NAA10 is mainly found in complex with NAA15, both
ribosome-and non-ribosome associated [31, 32]; however,
there also exists a pool of non-NAA15 bound NAA10
[31]. Due to a conformational change in NAA10 upon
NAA15 association, NAA10 alone has an altered substrate
specificity, preferring acidic N-termini [31, 33]. Further,
non-NAT functions of NAA10 as a lysine acetyltransferase
(KAT) or as a non-catalytic regulator have been proposed
[34–38]. Loss of NAA10 leads to developmental defects or
embryonic death in several model organisms [34, 39–41].
Hereditary or de novo germline variants in the
X-chromosomal NAA10 gene is associated with devel-
opmental syndromes and non-syndromic developmen-
tal delay in humans. A NAA10 S37P missense
mutation is the cause of the Ogden syndrome, an ex-
tremely rare disease in which affected boys have an
aged appearance, craniofacial anomalies, cardiac prob-
lems including arrhythmia, and where all affected
boys have died by age 16 months [42]. This mutation
affects NatA complex formation and leads to lowered cell
proliferation, larger cell size and reduced Nt-acetylation of
some NatA substrates [6, 42]. One splice-donor mutation
was found to lead to Lenz microphthalmia syndrome,
causing small or missing eyes, intellectual disability and
skeletal, cardiac, and renal problems [43]. Various other
mutations lead to non-syndromic developmental delay
and seizures in males and females [44, 45], a novel intel-
lectual disability syndrome in two brothers carrying the
same mutation [46], intellectual disability, developmental
delay and cardiac abnormalities in three brothers from
two families [47], and non-syndromic intellectual disability
with delayed language and motor development in a female
proband [48]. The NAA10 c.247C > T p.R83C missense
mutation is recurrent, previously having appeared de novo
in one male and seven female patients, generally manifest-
ing with moderate to severe intellectual disability and de-
velopmental delay, though only the boy had EEG
anomalies [49]. While NAA10 mutations have a
heterogenous clinical picture, with no clear
genotype-catalytic activity-phenotype correlation [47],
some features are seen in many or most patients; intellec-
tual disability, developmental delay, growth failure, and
cardiac anomalies. Here, we present the c.248G >A
p.R83H variant, found in two boys, aged 15 and 12 with
hyperactivity, limited language development, developmen-
tal delay, intellectual disability and hypertrophic cardio-
myopathy. The NAA10 R83H mutation leads to a
substantial decrease in NAA10 catalytic activity, support-
ing the hypothesis that this variant causes a loss of
NAA10-mediated acetylation and is the cause of the ob-
served phenotypes. Based on structural models of the
variant, we predict that this reduced catalytic activity is
due to impaired Ac-CoA binding.
Methods
Trio exome sequencing
A trio-based whole-exome sequencing approach was
undertaken. For patient 1, whole exome sequence was
performed as described [50]. The NAA10 variant was veri-
fied by targeted Sanger sequencing. DNA from patient 2
and parents were subjected to exome capture using Nim-
bleGen SeqCap EZ MedExome (Roche), followed by se-
quencing on an Illumina NextSeq550 to a mean coverage
of 91x, with 94% of targeted bases covered with minimum
20x coverage. Raw reads were aligned using the
Burrows-Wheeler Alignment tool (BWA-MEM) v. 0.7.15
[51] and the GATK Best Practice pipeline v. 3.8–0 was
used for variant calling [52]. Annotation and filtering of
variants was performed using VarSeq 1.5.0 (Golden Helix).
The NAA10 variant was verified by targeted Sanger se-
quencing. Informed consents were obtained from patient
indexes and family members.
Multiple sequence alignment, conservation scores and
structural model
Multiple sequence alignments were created using Clus-
talX [53] and the illustration and conservation scores
using Jalview [54]. The input sequences were: human
NAA10 (Uniprot ID: P41227), Mus musculus Naa10
(Uniprot ID: Q9QY36), Rattus norvegicus Naa10 (Uni-
prot ID: D3ZUQ2), Xenopus laevis naa10 (Uniprot ID:
Q7ZXW3), Danio rerio naa10 (Uniprot ID: Q7T3B8)
and Saccharomyces cerevisia ARD1 (Uniprot ID:
P07347). The NAA10 structural model is from the hu-
man NatA complex (PDB ID: 6C9M) [55]. The image
was obtained by aligning this structure to the structure
of Schizosaccharomyces pombe (4KVM) [33], which was
solved with CoA and the substrate peptide SASE. The
structure alignment and figure generation was per-
formed using PyMol [56].
In silico mutagenesis
NAA10-WT and NAA10-R83H from the human NatA
complex (PDB ID: 6C9M [55]) were aligned in PyMOL to
NAA10 from the S. pombe NatA complex (PDB ID: 4KVM
[33]). In order to calculate the electrostatic potential of the
two variants, these chains were uploaded to the Adaptive
Poisson-Boltzmann Solver (APBS) PDB2PQR webserver
[57–59] PDB2PQR makes preparatory changes to the PDB
file by optimizing hydrogen bond, repairing heavy atoms,
assessing pKa values and assigning charge and radius pa-
rameters [59]. The resulting PQR file was then solved for
continuum electrostatic potential by the APBS software.
Output files from the APBS were visualized in PyMOL and
the chains were aligned. Both PDB files were prepared and
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calculated with the same parameters, optimized for cellular
conditions. The molecular mechanical forcefield, Amber
[60] and the heuristic pKa calculation software PROPKA
[61] were used to generate the PQR at pH 7.4. Following
the PQR preparations, APBS was set to utilize a
manually-configured multigrid calculation, where the auto-
matically suggested dimensions were applied. “Ionic
strength of the solvent” was set to that of 0.15M NaCl with
ion radius of 1.5 Å. No electrostatic energies were calcu-
lated, and the output was set to “write out the electrostatic
potential in units of kbT/ec (multigrid and finite element)”.
The APBS was then launched with the remaining parame-
ters unchanged. The output PQR file from the APBS was
then opened in PyMOL and visualized in surface view.
Preparation of plasmids
In order to study the NM_003491.3 c.248G > A,
p.(R83H) missense variant, a bacterial expression vector
pETM-41/His-MBP-NAA10 was modified by
site-directed mutagenesis (Q5® Site Directed Mutagen-
esis Kit, New England Biolabs) according to the manu-
facturer’s protocol. The primers used for mutagenesis
were NAA10 G248A p.R83H fwd (5′-CAACCTCCT
CGGCCTGCCCGA) and NAA10 G248A p.R83H rev
(CAGTGCTGCATGTTCATTAGGTC), with an anneal-
ing temperature of 69 °C. The plasmid was verified by
sequencing.
Protein expression in E.coli BL21 cells
To study the impact of the novel variant on in vitro catalytic
activity, a two-step purification of His/MBP-NAA10-WT
and His/MBP-NAA10-R83H expressed in BL21 Star DE3 E.
coli was carried out essentially as described [44].
In vitro colorimetric acetylation assays
The catalytic activity of the novel NAA10-R83H variant
was compared with NAA10-WT by performing both time
dependent and substrate dependent DTNB-based acetyl-
ation assays. In the substrate dependent assay, 50 μL reac-
tions containing 100 nM His-MBP-NAA10-WT or
NAA10-R83H, 300 μM peptide substrate (either EEEI
A, DDDIA, MLGPE or SESSS, short for EEEI
AALRWGRPVGRRRRPVRVYP,DDDIAALRWGRPVG
RRRRPVRVYP, MLGPEGGRWGRPVGRRRRPVRVYP,
and SESSSKSRWGRPVGRRRRPVRVYP, where the
part in bold is the variable N-terminus and the rest of
the amino acid sequence is identical between the pep-
tides), 300 μM Ac-CoA, 1 x acetylation buffer (50 mM
Tris-HCl, 1 mM EDTA and 10% glycerol, pH 8.5), in-
cubated for 20 min at 37 °C. Blank reactions incubated
in the absence of enzyme. The reactions were stopped
using 100 μL quenching buffer (3.2 M guanidine-HCl,
100 mM Na2HPO4, pH 6.8), at which time the blanks
were added enzyme in equal proportion to the
reactions. To indicate the degree of acetylation for the in-
dividual reactions, 25 μL saturated solution of DTNB in
DTNB buffer (100mM Na2HPO4, 10mM EDTA, pH 6.8)
was added to each reaction. The time dependent assay
was carried out using only EEEIA as a substrate, and reac-
tions were quenched at different times (after 10, 20 and
30min); the procedures for the assays were otherwise the
same. Absorbance was measured at 412 nm using TECAN
Infinite® 200 PRO plate reader.
Results
Description of patients
Patient 1 is the only child born to non-consanguineous
parents. His birth weight was 3.25 kg (25th centile).
There were no antenatal or neonatal complications. His
father has microcephaly with mild learning difficulties;
his mother attended mainstream school but left school
early. Patient 1 presented with developmental delay at
age 2. Early milestones: he sat at 9 month, walked age 2
years 2 months, he had very poor speech development,
only has ~ 300 words with 2–3 worded sentences aged
15 years. He was diagnosed with coeliac disease aged 5
years 5 months (his father also has coeliac disease). He
had short stature but this resolved once treated for
coeliac disease. He has transient neutropenia of infancy
which resolved. He developed epilepsy aged 13 years 10
months. He wears glasses for astigmatism. He has a his-
tory of chronic constipation. He has behavioural issues
including poor concentration, and can be quite volatile
and aggressive. He has been assessed as having a mod-
erate learning disability & attends a special school. His
cardiac assessment revealed a normal cardiac examin-
ation aged 2 years 9 months and again 15 years with a
normal long QT interval. However, he had been noted
to have mild concentric left ventricular hypertrophy on
an assessment in between. He is hypermobile. He takes
sodium valproate for epilepsy and movicol for his con-
stipation. At 2 years 1 month of age his weight was 11.4
kg (9th centile)/height 80.5 cm (> 0.4th centile), and
24.6 kg (>3rd centile)/height 124.4 (> 0.4th centile) cm
at 10 years 7 months. Occipitofrontal circumference
(OFC) aged 14 years 7 months 52.5 cm (<10th centile)
(His father’s OFC is 53.5 cm (< 0.4th centile). He has a
tented upper lip but no other dysmorphism. Trio
exome revealed a maternally inherited NAA10
(NM_003491.3) c.248G > A, p.R83H variant which was
further confirmed by Sanger sequencing. The mother’s
parents are both dead precluding further segregation
studies; however her two healthy brothers tested nega-
tive for this variant.
Patient 2 is the second child to non-consanguineous
parents. He was born after 39 weeks of gestation. Birth
weight 3344 g (median), length 51 cm (median), and head
circumference 36 cm (+1SD). He had neonatal-onset
Ree et al. BMC Medical Genetics          (2019) 20:101 Page 3 of 8
hypotonia and poor feeding. He was breastfed to some ex-
tent until he was five years old. He presented with devel-
opmental delay at 12months. Early milestones: he sat at 6
month, walked at age 2 years 3months, from 18months
he rolled around indoors. He had very poor speech devel-
opment and only uses a limited number of words with 2–
3 worded sentences aged 12 years. He has behavioural is-
sues including poor concentration, but is a quite happy
and very active boy. He had eczema and very fine and
sparse scalp hair until 3 years of age. He has a tendency to
develop mild fevers of unknown origin. He does not have
epilepsy. His height has been constantly at -2SD since 2
years of age; at 12 years his height was 142 cm. Dys-
morphic features at 12 years of age was rather mild in the
form of large ears, and rather closely spaced eyes. Cardiac
examination revealed a structurally normal heart, i.e. no
congenital malformations. Measurements of ventricular
wall thickness were taken at end-diastole, indexed to body
surface area and z-score measurements calculated as de-
scribed by the Pediatric Heart Network [62]. This revealed
a predominantly septal hypertrophy (z-score + 8.3) and re-
duced end-diastolic diameter of the left ventricle (Fig. 1).
Although the septal hypertrophy caused narrowing of the
left ventricular outflow tract, it did not cause obstruction
to flow (Fig. 1 A and B, Additional file 1: Video S1). The
ECG was normal except for borderline prolongation of
the corrected QT-interval (420 milliseconds, Fig. 1 C). To
assess for potential arrhythmias a 48-h Holter monitoring
was performed. The heart rate varied between 66 to 165
bpm, and on average was 106 bpm. No arrhythmias were
detected. Trio exome sequencing revealed a mosaic de
novo NAA10 ((NM_003491.3) c.248G > A, p.(Arg83His))
hemizygote missense variant, with a mosaic degree of
75%. The variant was confirmed by Sanger sequencing.
Functional testing
To assess the effect of the R83H mutation on NAA10 cata-
lytic activity, we performed site-directed mutagenesis to ob-
tain the R83H mutant NAA10 protein. We expressed
wild-type NAA10 (NAA10-WT) and NAA10-R83H as
6xHis-tagged maltose-binding protein (MBP)-fusion proteins
in E. coli, purified them, and performed in vitro
Nt-acetylation assays against model substrate peptides. These
peptides have identical C-termini but differ in the 7N-ter-
minal amino acids. Such setups are commonly used to deter-
mine the substrate preferences of NATs, and to measure
catalytic activities of NAT mutant enzymes [35, 48, 49]. We
were able to purify NAA10-R83H in monomeric form under
the same conditions as NAA10-WT. Both WT and R83H
eluted at around 80mL, and the R83H mutant was at the ex-
pected size. In vitro, monomeric NAA10, not bound to the
NatA complex, prefers substrates with acidic N-termini [31],
represented in our panel by EEEIA and DDDIA. The NatA
canonical substrate SESSS and the NatE substrate MLGPE
were also included. We found no difference in the prefer-
ence for different peptides between NAA10-WT and
NAA10-R83H, but the catalytic efficiency was severely di-
minished in the R83H mutant (Fig. 2a). Timecourse ex-
periments with the EEEIA peptide confirmed that the
catalytic activity is significantly reduced (Fig. 2c).
Structural conservation and surface charge of NAA10-R83H
A structural model was made by aligning the human
NAA10 chain from the structure of the human NatA com-
plex (PDB ID: 6C9M, [55]) to the corresponding chain of
the S. pombe (PDB ID: 4KVM, [33]), the latter of which
was solved with CoA and substrate peptide. This showed
Fig. 1 Cardiac hypertrophy in patient 2. Transthoracic echocardiography
showing the left ventricle in a parasternal long axi and b apical 3-
chamber view. Please note how the hypertrophy predominantly affects
the interventricular septum with relative sparring of the apical and
posterior regions. Red marker on EKG trace shows temporal relation to
heart cycle. LV, left ventricle; Ao, aorta; LA, left atrium; IVS, interventricular
septum. c Standard electrocardiogram (EKG) in patient 2. Note the
borderline prolonged QTc
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that the mutation site R83 is in proximity to the negatively
charged phosphate group on the ribose ring of CoA (Fig.
2b). A defining feature of GNAT acetyltransferases is a core
fold which includes an Ac-CoA binding region, four
alpha-helices and six or seven beta-sheets [1]. R83 is part of
the Ac-CoA binding region of NAA10, though R82 is even
more conserved (Fig. 2d). We find an arginine in the same
position in crystal structures of NAA20 [63], NAA40 [64]
NAA50 [65], and NAA60 [66]. At physiological pH, argin-
ine is expected to be protonated to a greater degree than
histidine. We performed in silico mutagenesis in NAA10
from the hNatA structure [55] to determine whether the
Ac-CoA binding region had altered electrostatic properties
(Fig. 3), and found that the surface near Ac-CoA appears
less basic when R83 is mutated into a histidine.
Discussion
NAA10 is predicted to Nt-acetylate around 40% of the hu-
man proteome [1] as part of the NatA complex on the
ribosome [29], but it may also be a monomeric NAT enzyme
not associated with the ribosome [31]. In addition, both lysine
acetyltransferase activities and acetyltransferase-independent
functions have been proposed for NAA10 [34–38]. NAA10 is
essential for normal development in all surveyed model or-
ganisms [34, 39–41]. Several mutations in human NAA10
are known, with substantial heterogeneity in presentation
and severity of symptoms, yet with the common features
of intellectual disability, delayed developmental and
growth failure, and occasionally cardiac anomalies [42–44,
46–49, 67, 68]. In many cases, NAA10 mutations result in
a decrease in catalytic activity (S37P, Y43S, I72T, R83C,
V107F, V111G, R116W, and F128 L), while others
destabilize NAA10 (Y43S, I72T, V111G, F128I, F128 L).
The mutation causative of Ogden syndrome, S37P, leads
to impaired NAA10 interaction with other NatA complex
components [6], in addition to having decreased catalytic
activity [42]. A new potential mechanism for how NAA10
mutation may cause developmental phenotypes is
Fig. 2 Functional testing of NAA10-R83H. MBP-NAA10 fusion proteins (wild-type (WT) or R83H) were tested for in vitro NAT activity against
substrate peptides with indicated N-termini a or against EEEIA-peptide for the indicated reaction times c. Sequences of the peptide substrates
are EEEIAALRWGRPVGRRRRPVRVYP, DDDIAALRWGRPVGRRRRPVRVYP, MLGPEGGRWGRPVGRRRRPVRVYP, and SESSSKSRWGRPVGRRRRPVRVYP
(bold indicating the variable N-termini of the peptides, while the rest of the peptide sequence is identical between them). b Structure of the
human NAA10 protein (PDB ID: 6C9M) superimposed on the substrate from the Schizosaccharomyces pombe NAA10 structure (4KVM) Substrate
peptide (SASE) is shown in green, while the mutation site Arg83 is shown in red. CoA is shown as a licorice model colored according to element.
d Multiple sequence alignment of NAA10 from Homo sapiens, Mus musculus, Rattus norvegicus, Xenopus laevis, Danio rerio, and Saccharomyces
cerevisiae. Conservation score is calculated by Jalview (http://www.jalview.org/), with * signifying perfect conservation
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acetyltransferase-independent, however. Three previously
described variants (S37P, V107F and R116W) were found
to have decreased binding to imprinting control regions,
potentially leading to dysregulation of genomic imprinting
[34]. NAA15 mutations have also been described, with an
overlapping phenotype to NAA10 mutations. Patients had
several different indels or splice-site mutations, and pre-
sented with neurodevelopmental problems including intel-
lectual disability, autism, motor function impairment and
developmental delay [69]. Taken together, these findings
suggest that NatA may have a critical role in nervous sys-
tem development.
In this study, we present two male patients with a novel
NAA10 variant, R83H. One patient presented with
developmental delay, very limited language development
at age 15, epilepsy, behavioural issues, but normal cardiac
function. The other patient with a similar phenotype with
developmental delay, very limited language development
at age 12, ADHD like behaviour and hypertrophic cardio-
myopathy. This is a similar clinical picture to what is
known in some of the other described NAA10 patients
with developmental delay and a cardiac phenotype.
Functional testing of in vitro catalytic activity was
performed to determine whether the mutant enzyme
was active. We found that NAA10-R83H had an un-
changed substrate preference profile (Fig. 2a), but a
greatly reduced catalytic activity. A time-course assay
further bolstered this conclusion (Fig. 2c). The recurring
R83C variant of NAA10 likewise had a greatly reduced
catalytic activity [49], supporting the importance of R83
for NAA10 catalytic function.
We performed in silico mutagenesis to model the im-
pact of this mutation on the surface charge of NAA10
(Fig. 3). While an arginine in this position contributes to
a positively charged pocket, which can interact favorably
with the phosphate groups on Ac-CoA, mutation to
histidine decreases the positive charge density in this
region. Several patients with a R83C variant at the same
site have been reported. This variant likewise leads to a
sharp decrease in catalytic activity [49]. The previously
described R83C mutation and the loss of activity in
R83H described here point to R83 being important for
NAA10 enzymatic activity. The altered charge density in
our in silico model suggests that perturbed interaction
between NAA10-R83H and Ac-CoA may be the reason
for the impaired catalytic activity. This is consistent with
the hypothesis that the R83H variant leads to decreased
NAA10 catalytic activity and that this is causing the
symptoms observed in these two cases. Whether this is
due to a loss of NAT- or KAT-activity, and if so which
subset of substrates are mechanistically responsible for
the phenotypes, is not clear.
Conclusions
We identify a novel missense variant of NAA10, and
present evidence to support that this variant is causative
of the symptoms seen in the two cases.
Additional file
Additional file 1: Video S1. Transthoracic echocardiography showing the
left ventricle from an apical 3-chamber view (identical to Fig. 1) during two
heart cycles in color compared mode. Please note that although there is no
obstruction to flow in the left ventricular outflow tract (LVOT), a slight turbu-
lence does occur along where the hypertrophic septum protrudes into the
LVOT. (MOV 793 kb)
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